Company profile
Apogenix company profile
Apogenix is a clinical stage biopharmaceutical company developing novel protein therapeutics for the treatment of cancer and inflammatory diseases. The compound´s mechanism of action is either based on the targeted modulation of the programmed cell death (a.k.a. apoptosis - ἁπόπτωσισ is used in Greek to describe the "falling off" of leaves from trees) or on the inhibition of tumour cell growth. The lead product candidate of the company, APG101, is currently in a controlled phase II proof of concept study with GBM patients (GBM: Glioblastoma multiforme).
Business identity
- Website
- http://apogenix.com
- Contact email
- [email protected]
- Phone number
- +49 6221 58608-0
- Operating status
- Active
- Company type
- For Profit
- Employee range
- 00051-00100 employees
- Revenue range
- $1K+
- Founded
- 2005-01-01
Headquarters
- Headquarters
- Heidelberg, Baden-Wurttemberg, Germany
- Postal code
- 69120
- Country code
- DE
- Continent
- Europe